Pivotal phase III will require at least 300 patients and will take 2 years+ to allow for recruitment etc...therefore late 2010 means that should be completed by mid 2013 and marketing approval if all goes will then be mid/late 2014
The FDA usually require some trial centres to be in the US in any pivotal phase III study so I'm a bit surprised that they only plan a trial in Europe under EMEA
With patent expiry in 2014 orphan drug status is key in trying to extend the monopoly market period, without it CVAC is dead
Add to My Watchlist
What is My Watchlist?
